Drugs / PTP-001
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04632966 | Feb 2021 → Sep 2022 | osteoarthritis, knee | Bioventus LLC | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05100225 | Sep 2021 → Oct 2022 overdue | osteoarthritis, knee | Bioventus LLC | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07219771 | Oct 2025 → Apr 2027 expected | osteoarthritis, knee | Doron Therapeutics Inc. | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PTP-001 | “Allogeneic human placental tissue particulate (PTP-001) is administered as a single intra-articular injection to the target knee after resuspension with saline.” NCT07219771 ↗ |
| Action | Inhibit | “ability to reduce cartilage degradation by suppressing protease expression” PMID 39704612 ↗ Dec 2024 |
| Modality | Protein / enzyme biologic | “PTP-001 represents a promising biologic treatment for osteoarthritis” PMID 34023528 ↗ May 2021 |
| Route | Other | “single intra-articular (IA) injection of PTP-001” NCT04632966 ↗ |
| Target | ADAMTS5 | “ADAMTS5 expression was reduced in the chondrocyte compartment following treatment with PTP-001 relative to PRP.” PMID 36912174 ↗ Mar 2023 |
| Target | MMP13 | “PTP-001 and LR-PRP (but not LP-PRP) significantly reduced chondrocyte MMP13 expression in cultures containing IL-1-pretreated synoviocytes.” PMID 36912174 ↗ Mar 2023 |
| Target | TNF | “PTP-001 and PRP preparations were able to reduce TNF-α production in macrophage cell cultures” PMID 36912174 ↗ Mar 2023 |